FRANKFURT (Reuters) – German drugmaker Merck said on Wednesday it had agreed to supply its potential COVID-19 drug Rebif to European Union countries should orders be placed for the treatment. The comment followed a Reuters report earlier on Wednesday about a d... More »
(Reuters) – The U.S. Food and Drug Administration said on Wednesday it approved Merck & Co Inc’s Keytruda for a hard-to-treat form of bladder cancer, making it the first new treatment for the cancer in more than two decades. The therapy was approved for patien... More »
(Reuters) – Merck & Co (MRK.N) said on Friday it expects to make licensed doses of its recently approved Ebola vaccine available in the third quarter of 2020 and price the single-dose injection at the lowest possible access price for poor and middle-income cou... More »
(Reuters) – Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients. The results showed the drug, Bavencio, in combination with, or as a follow-on treatment ... More »
CHICAGO (Reuters) – Merck & Co’s immunotherapy Keytruda improved survival as a stand-alone treatment for newly-diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer, new data released on Sunday showed, further cementi... More »
FRANKFURT/NEW YORK (Reuters) – Generic drug maker Mylan (MYL.O) is in advanced discussions to acquire Merck KGaA’s (MRCG.DE) consumer health business after other bidders failed to meet the German company’s price expectations, people familiar with the matter sa... More »
FILE PHOTO: A cyclist rides past a logo of drugs and chemicals group Merck KGaA in Darmstadt, Germany, January 28, 2016. REUTERS/Ralph Orlowski/File Photo LONDON/FRANKFURT (Reuters) – The sale of Merck KGaA’s (MRCG.DE) consumer health unit has been thrown off ... More »
The logo of German pharmaceuticals company Merck is seen in front of the company’s headquarters in Darmstadt, Germany, May 16, 2016. REUTERS/Kai Pfaffenbach FRANKFURT (Reuters) – Germany’s Merck KGaA (MRCG.DE) is reviving plans to bring an oral multiple sclero... More »
LOS ANGELES (Reuters) – Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10... More »
Merck & Co (MRK.N) on Friday said quarterly sales of its Keytruda cancer immunotherapy exceeded $1 billion for the first time, but it withdrew an application for European use of the drug in lung cancer, raising questions about future sales. More »
Giving Merck & Co's immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial. More »
Germany's Merck KGaA is considering selling its $1 billion consumer health unit to meet its financial targets as a decline in its liquid crystal business forces it to review its strategy. More »
remitting form of MS.) More »
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck’s pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky Merck & ... More »
A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed/File Photo Merck & Co’s cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announc... More »
U.S. health regulators on Thursday approved a drug developed by Merck KGaA and Pfizer Inc that helps the immune system to fight a rare form of skin cancer once it has spread to other parts of the body. More »
Merck & Co Inc said on Tuesday it had got a nod from the U.S. Food and Drug Administration for its already-approved immunotherapy drug Keytruda as a treatment for a type of blood cancer. More »
Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer’s drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind... More »
Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda. More »
A trader passes by a screen displaying the tickers symbol for Bristol-Myers Squibb on the floor at the New York Stock Exchange, April 25, 2013. REUTERS/Brendan McDermid New data is likely to prompt doctors to abandon Bristol-Myers Squibb’s immunotherapy Opdivo... More »
SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C. The damages award is far less than the $2... More »
Merck & Co’s drug to reverse the effects of muscle relaxants used in surgery is safe and effective enough to warrant approval, an independent panel to the U.S. Food and Drug Administration said. The drug, which goes by the chemical name of sugammadex, has repe... More »
The U.S. Food and Drug Administration on Friday approved Merck & Co Inc’s immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker. The FDA approval for Keytruda in advanced non-small cell... More »
An experimental antibody developed by Merck & Co Inc was shown in pivotal studies to reduce by about 10 percentage points the risk that infection with Clostridium difficile bacterium, which can cause a deadly diarrhea, will recur. In the United States, C. diff... More »
